

# Mongolian Breast Cancer Incidence: A Follow-up Report

Alaina Shreves<sup>1</sup>, Ganmaa Davaasambuu<sup>2</sup>, Preethi Raj<sup>1</sup>, Rebecca Troisi<sup>1</sup>

<sup>1</sup>Division of Cancer Epidemiology and Genetics, National Institutes of Health, 9609 Medical Center Drive, MSC 9776, Bethesda, MD, 20892, USA. <sup>2</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, 677 Huntington Blvd., Boston, MA, 02115, USA.

## Abstract

**Objective:** Understanding variance in global breast cancer incidence rates may help identify risk factors and could lead to increased efforts for prevention. In our previous study on breast cancer in Mongolia from 1998-2005, we reported that the incidence of breast cancer, though on the rise, remains lower in Mongolia than in adjacent Asian countries. Through the addition of almost a decade of data (2006-2014), we provide a study update and describe trends in breast cancer incidence and staging distributions within Mongolia, with further analyses examining women in urban and rural regions. **Methods:** Age-standardized breast cancer incidence and staging distributions were obtained from the Mongolian National Oncology Center and were used to describe trends in cancer over time. **Results:** Our findings indicate that the overall incidence of breast cancer has continued to increase in Mongolia, with rural women still experiencing lower risk than their urban counterparts. Given similarities in cancer staging, the observed geographic variation does not appear to result from differences in cancer stage at diagnosis over time or by region. **Conclusions:** Considering the variation in rural and urban populations, data from this study could be used to better understand the influence of westernization on cancer risk in Asian countries and beyond. Further research on demographic shifts in breast cancer incidence within Mongolia may elucidate novel risk factors explaining variations active among other populations.

**Keywords:** Breast cancer- urban-rural- Asia- international- cancer staging

*Asian Pac J Cancer Care*, 5 (3), 161-165

Submission Date: 05/08/2020    Acceptance Date: 07/05/2020

## Introduction

Breast cancer is a leading cause of mortality in women in developed and developing countries around the world. While Asia is responsible for a large proportion of the global burden of cancer, breast cancer rates across the continent have been historically low in comparison with more westernized countries [1]. The incidence and mortality rates of breast cancer in Mongolia are lower than in other Asian countries, at 8.0 per 1,000 [1]. However, rates have been steadily increasing on an annual basis and vary by geographic regions, with the highest incidence rates in the most urban districts [2]. A similar urban-rural difference has been reported in other Asian countries, engendering questions about the potential long-term impacts of westernization and lifestyle change on health [3].

In our previous study analyzing breast cancer rates in Mongolia from 1998 to 2005, we reported that

the incidence of breast cancer, though on the rise, remained lower in Mongolia than in other Asian countries [4]. Since our original paper was published, other studies describing similar trends have raised concerns about the growing cancer risk for the region. Using registry data from 2009-2013, researchers identified a substantial and consistent increase in breast cancer, supporting the trend that was first described in our original paper [4].

Other studies have considered the implications of an increasing prevalence of breast cancer by studying shifts in survival rates. Although cancer survival data is limited, emerging evidence suggests that most breast cancers in Mongolia are diagnosed at a late stage, as the 5-year breast cancer survival rate is considerably lower than that observed in more westernized countries [5-6]. Since mammography screening is known to reduce breast cancer mortality in Western countries, the lack of

## Corresponding Author:

Ms. Alaina Shreves

Division of Cancer Epidemiology and Genetics, National Institutes of Health, 9609 Medical Center Drive, MSC 9776, Bethesda, MD, 20892, USA.

Email: [alaina.shreves@nih.gov](mailto:alaina.shreves@nih.gov)

a population-based screening program in Mongolia is of interest to researchers and clinicians. According to recently published national guidelines, breast screening is not currently instituted in Mongolia due to its low relative incidence compared to other cancers and limited resources [7]. Consequently, Mongolian women predominantly rely on self-screening and routine clinical exams to detect breast cancers. As a potential result, Mongolian women are more likely to be clinically diagnosed with later-stage tumors, leading to an increased rate of mortality from breast cancer [4-6]. Although evidence has not yet been published, one possibility is that insufficient access to health services could contribute to a delay in diagnosis. Thus, we hypothesize that limited access to clinical exams in more remote regions of Mongolia could result in a higher risk of later-stage breast cancer among rural women.

As described in our original paper and supported by other recent epidemiological studies, geographic variations in breast cancer risk exist within Mongolia. We previously reported that the annual percent increase in breast cancer rates was higher in urban areas than in rural areas. We also found that breast cancer staging was similar across time and geographic groups, with most cases at stage III or IV at diagnosis [4]. Researchers have since proposed that risk factors associated with westernization such as lifestyle factors (e.g., diet, physical activity), breast density, and hormone levels could account for geographic variations in Mongolia, but more data are needed to comprehensively address these hypotheses [8].

Here we provide an update to our original study and analyze breast cancer trends in Mongolia through the addition of nearly a decade of cancer registry data (2006-2014). With the additional data, we describe variations in breast cancer risk and breast cancer staging within Mongolia, overall and for urban and rural populations over time. We present a more thorough analysis of incidence and risk that is crucial to understanding the burden of breast cancer in Mongolia. Given the demographic shift towards a more Western-influenced lifestyle among many Asian countries, temporal data from Mongolia could tell us more about the inherent biological changes and risks that result from increased urbanization.

## Materials and Methods

We used annual age-specific breast cancer registry data available from the Mongolian National Oncology Center (NOC) to describe trends in the population from 1995 to 2014. In Mongolia, incident cancer cases are first reported to one of the 21 Mongolian aimags, provinces, and then submitted to the NOC. The NOC data are presented by geographical area and population density, allowing separate analyses of rates among rural-urban groups.

Using annual population data for each aimag, we calculated age-specific breast cancer incidence rates for women in 5-year age groups. Age-specific rates (i.e., the number of cases divided by the number of women in that

age group) were then multiplied by the corresponding number of women in the World Standard Million. The World Standard Million is a standard population value calculated by the Surveillance, Epidemiology and End Results (SEER) program [9]. Each value was divided by the total number of women above the age of 20 in the World Standard Million. Products were summed across age groups for each calendar year and province and then multiplied by 100,000. In summary, we calculated a weighted average of the age-specific rates, weighing each rate by the corresponding fraction of the World Standard Million. We then analyzed the age-standardized rates by the calendar year of diagnosis, urban-rural residence, and breast cancer stage.

## Results

Since the data from the NOC are presented by geographic areas and population density, it is important to understand population demographics for the country of Mongolia. Based on estimations for July 2020, Mongolia's population is about 3.2 million and is relatively young compared to other countries [10]. In 2019, 31.2% of the population was <15 years of age and 4.1% of the population was >65 years of age [11]. The median age of females in Mongolia was 30.7 years old and life expectancy for women in Mongolia is 75.2 years of age [10-11]. These values have changed since our previous publication, showing an increase in the overall population and an aging of the population.

Although many Mongolians live as nomads or semi-nomadic herdsmen, the population of Mongolia has experienced a recent shift in urbanization [10]. In 2019, approximately 67.8% of the population resided in urban areas, while in 2008, only 54.6% of the population were considered urban [4-11]. In our original paper, we reported that approximately 60% of the population lived in the capital city of Ulaanbaatar (UB), whereas in 2018, an estimated 46.1% of the population resided in UB [4-11]. As degrees of urbanization continue to change in Mongolia, the potential health effects of western lifestyles remain relevant and of increasing interest.

Based on our analyses, the updated data from the NOC indicate a steadily increasing incidence of breast cancer in Mongolia, further supporting the findings in our original paper. As shown in Figure 1, the updated rates indicate that the overall incidence of breast cancer has continued to increase in Mongolia, with rural women still experiencing a lower risk than urban women. These results support our earlier findings and suggest further research on demographic shifts in breast cancer incidence within Asia is necessary.

To address the hypothesis that greater access to clinical exams could lead to earlier diagnoses for urban women, we analyzed tumor staging by comparing the proportion of women diagnosed at each cancer stage from 1998 to 2014. As shown in Figure 2, breast cancer staging was found to be relatively consistent between women in urban and rural Mongolia. These results suggest that breast cancer staging distributions have not changed substantially over




Figure 1. Age-standardized Breast Cancer Incidence Rates in Mongolia by Population (cases/100,00) from 1998-2014

time in Mongolia.

**Discussion**

Our findings indicate that the overall incidence of breast cancer has continued to increase in Mongolia, with rural women experiencing a lower cancer risk than their urban counterparts. While the overall prevalence of breast cancer screening in Mongolia is low compared to other countries, greater access to clinical breast screening examinations in urban areas could result in geographic

differences in incidence [8-12]. Given Mongolia’s demographic shifts and a steady increase in urbanization, the urban-rural incidence differences raise questions about the influence of westernization on breast-cancer risks.

Mongolia’s high breast cancer mortality rate led us to consider that a lack of available routine mammographic screening could result in a higher prevalence of late-stage cancers in rural women. However, our results indicate that breast cancer staging was similar for cases in urban and rural women. For both groups, stage III accounted for the highest proportion of breast cancer cases while stage I accounted for the lowest proportion. This high prevalence of late-stage cancer is compatible with findings from other studies and perhaps reflects the absence of a national screening program, rather than regional differences [13]. Although we did not find a significant difference in cancer staging over time, evidence from other sources finds that staging has changed for many cancers in Mongolia. In 2018, Mongolia’s Annual Health Report found that 76.1% of incident cancers were diagnosed at later stages, compared to 90% in 2008 [4-11].

Limitations of this report are like those that impacted our original study. Given the high tendency for back and forth migration over time in Mongolia, misclassification of women’s residence as urban or rural could have occurred. However, unless women are systematically relocating to urban areas before a breast cancer diagnosis, the misclassification of residence concerning cancer would be considered random. Additionally, the completeness of the data could have affected our findings. Interviews with the individuals involved in the registry have led us to believe that cancer reporting in Mongolia is generally high. Since cancers may need to advance before being diagnosed, the accuracy and completeness of diagnoses are unknown. However,




Figure 2. Breast Cancer Incidence by Percent Stage at Diagnosis for Mongolia from 1998-2014

the non-localized stage of many of the cancers suggests that advanced disease is being diagnosed and reported to the NOC.

The additional data included in this short report strengthens our previous observation that breast cancer incidence in Mongolia is increasing and remains higher in urban provinces than in rural regions. The differing urban and rural incidence rates could imply an emerging difference between women living in traditional settings and those moving to urban areas, offering a possible explanation for why breast cancer incidence rates vary between Mongolia and more westernized Asian countries. We conclude that further research on demographic shifts in breast cancer incidence within Asia should be considered, as it may elucidate novel cancer risk factors active among other populations.

#### Funding Statement

This work was supported by the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, US Department of Health and Human Services.

#### Statement of Conflict of Interest

The authors declare no conflict of interest.

#### References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*. 2018 09 12;68(6):394-424. <https://doi.org/10.3322/caac.21492>
2. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International Variation in Female Breast Cancer Incidence and Mortality Rates. *Cancer Epidemiology Biomarkers & Prevention*. 2015 09 10;24(10):1495-1506. <https://doi.org/10.1158/1055-9965.epi-15-0535>
3. Shin H, Joubert C, Boniol M, Hery C, Ahn SH, Won Y, Nishino Y, Sobue T, Chen C, You S, Mirasol-Lumague MR, Law SC, Mang O, Xiang Y, Chia K, Rattanamongkolgul S, Chen J, Curado MP, Autier P. Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. *Cancer Causes & Control*. 2010 06 18;21(11):1777-1785. <https://doi.org/10.1007/s10552-010-9604-8>
4. Troisi R, Altantsetseg D, Davaasambuu G, Rich-Edwards J, Davaalkham D, Tretli S, Hoover RN, Frazier AL. Breast cancer incidence in Mongolia. *Cancer Causes & Control*. 2012 04 29;23(7):1047-1053. <https://doi.org/10.1007/s10552-012-9973-2>
5. Angarmurun D, Batzorig B, Undram L, Gantuya D, Chimedsuren O, Avirmed D. Breast Cancer Survival in Mongolian Women. *OALib*. 2014;01(05):1-5. <https://doi.org/10.4236/oalib.1100396>
6. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo e Silva G, Chen W, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, Bouzbid S, Hamdi-Chérif M, Zaidi Z, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Fabowale A, Bradshaw D, Somdyaala NIM, Kumcher I, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Diumenjo MC, Laspada WD, Ibañez SG, Lima CA, De Souza PCF, Del Pino K, Laporte C, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Latorre MRDO, Tanaka LF, Rebelo MS, Santos MO, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Noonan G, Turner D, Kumar E, Zhang B, McCrate FR, Ryan S, MacIntyre M, Saint-Jacques N, Nishri DE, McClure CA, Vriends KA, Kozie S, Stuart-Panko H, Freeman T, George JT, Brockhouse JT, O'Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Schwartz AG, Vigneau F, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Green MD, Miyagi K, Ruppert LP, Lynch CF, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Gershman ST, Knowlton RC, Alverson G, Copeland GE, Bushhouse S, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Rees JR, Riddle B, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Espinoza RE, Khan F, Aird KG, Beran T, Rubertone JJ, Slack SJ, Garcia L, Rousseau DL, Janes TA, Schwartz SM, Bolick SW, Hurley DM, Whiteside MA, Miller-Gianturco P, Williams MA, Herget K, Sweeney C, Johnson AT, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Farley S, Borchers R, Malicki R, Espinoza JR, Grandpre J, Wilson R, Edwards BK, Mariotto A, Lei Y, Wang N, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Zeng H, Demetriou AV, Mang WK, Ngan KC, Katakai AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Nakagawa H, Sato M, Tabori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Sato S, Yoshii M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Sanjaajmats E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajang S, Kamsa-ard S, Wiangnon S, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipai boon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Valerianova Z, Yordanova MR, Šekerija M, Dušek L, Zvolský M, Storm H, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Arveux P, Maynadié M, Mounier M, Woronoff AS, Daoulas M, Robaszkie wicz M, Clavel J, Goujon S, Lacour B, Baldi I, Pouchieu C, Amadeo B, Coureau G, Orazio S, Preux PM, Rharbaoui F, Marrer E, Trétarre B, Colonna M, Delafosse P, Ligier K, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Grosclaude P, Bossard N,

- Uhry Z, Bray F, Piñeros M, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Emrich K, Zeissig SR, Holleczeck B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Clough-Gorr K, Walsh PM, Sundseth H, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomini A, Magoni M, Ardizzone A, D'Argenzio A, Castaing M, Grosso G, Lavecchia AM, Sutura Sardo A, Gola G, Gatti L, Ricci P, Ferretti S, Serraino D, Zucchetto A, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Russo AG, Carrozzi G, Cirilli C, Cavalieri d'Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Borciani E, Seghini P, Maule MM, Merletti F, Tumino R, Mancuso P, Vicentini M, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Cesaraccio R, Pirino DR, Contrino ML, Tisano F, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Piffer S, Rosso S, Barchielli A, Caldarella A, Bianconi F, Stracci F, Contiero P, Tagliabue G, Ruge M, Zorzi M, Beggiano S, Brustolin A, Berrino F, Gatta G, Sant M, Buzzoni C, Mangone L, Capocaccia R, De Angelis R, Zanetti R, Maurina A, Pildava S, Lipunova N, Vincerževskienė I, Agius D, Calleja N, Siesling S, Larønningen S, Møller B, Dyzmann-Sroka A, Trojanowski M, Gózdź S, Mężyk R, Mierzwa T, Molong L, Rachtan J, Szewczyk S, Błaszczyk J, Kępska K, Kościńska B, Tarocińska K, Zwierko M, Drosik K, Maksimowicz KM, Purwin-Porowska E, Reca E, Wójcik-Tomaszewska J, Tukiendorf A, Grądalska-Lampart M, Radziszewska AU, Gos A, Talerczyk M, Wyborska M, Didkowska JA, Wojciechowska U, Bielska-Lasota M, Forjaz de Lacerda G, Rego RA, Bastos J, Silva MA, Antunes L, Laranja Pontes J, Mayer-da-Silva A, Miranda A, Błaga LM, Coza D, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova AG, Orlov AE, Kudyakov LA, Pikalova LV, Adamcik J, Safaei Diba C, Primic-Žakelj M, Zadnik V, Larrañaga N, Lopez de Munain A, Herrera AA, Redondas R, Marcos-Gragera R, Vilardell Gil ML, Molina E, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque MD, Navarro C, Ardanaz EE, Guevara MM, Fernández-Delgado R, Peris-Bonet R, Carulla M, Galceran J, Alberich C, Vicente-Raneda M, Khan S, Pettersson D, Dickman P, Avelina I, Staehelin K, Canejo B, Bouchardy C, Schaffar R, Frick H, Herrmann C, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolerio A, Konzelmann I, Matthes KL, Rohrmann S, Broggio J, Rashbass J, Fitzpatrick D, Gavin A, Clark DI, Deas AJ, Huws DW, White C, Montel L, Rachet B, Turculet AD, Stephens R, Chalker E, Phung H, Walton R, You H, Guthridge S, Johnson F, Gordon P, D'Onise K, Priest K, Stokes BC, Venn A, Farrugia H, Thursfield V, Dowling J, Currow D, Hendrix J, Lewis C. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet*. 2018 03;391(10125):1023-1075. [https://doi.org/10.1016/s0140-6736\(17\)33326-3](https://doi.org/10.1016/s0140-6736(17)33326-3)
7. Mongolia Ministry of Health. National Cancer Control Program 2007–2017 Mongolia. 2014. Available from: <https://www.iccp-portal.org/system/files/plans/NCCP%20Mongolia%202007-2017.pdf>. [Accessed: 1 February 2020].
  8. Demchig D, Mello-Thoms C, Khurelsukh K, Ramish A, Brennan PC. Mammographic Appearances in Mongolia: Causal Factors for Varying Densities. *Asian Pacific Journal of Cancer Prevention*. 2017 09;18(9). <https://doi.org/10.22034/APJCP.2017.18.9.2425>
  9. Surveillance Epidemiology and End Results. Standard Populations (Millions) for Age-Adjustment 2020. Available at <https://seer.cancer.gov/stdpopulations/>. [Accessed 1 March 2020].
  10. US Central Intelligence Agency. Mongolia 2020. Available at <https://www.cia.gov/library/publications/the-world-factbook/geos/mg.html>. [Accessed 1 March 2020].
  11. Center for Health Development. Health Indicators 2018. Health Indicators. 2017. <https://www.chd.mohs.mn/2019/sariin%20medee/2018eng.pdf>. [Accessed 1 March 2020].
  12. Moore MA, Aitmurzaeva G, Arsykulov ZA, Bozgunchiev M, Dikanbayeva SA, Iginov G, et al. Chronic Disease Prevention Research in Central Asia, the Urals, Siberia and Mongolia - past, present and future. *Asian Pac J Cancer Prev*, 2009; Volume 10 (6), p. 987-96. Available from: <https://pubmed.ncbi.nlm.nih.gov/20192571/>. [Accessed: 15 February 2020].
  13. Demchig D, Mello-Thoms C, Brennan PC. Breast cancer in Mongolia: an increasingly important health policy issue. *Breast Cancer: Targets and Therapy*. 2017 01; Volume 9:29-38. <https://doi.org/10.2147/bctt.s125584>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.